Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 7, 2015, Pages 1055-1068

  Sweeney, Melanie D ^a   Sagare, Abhay P ^a   Zlokovic, Berislav V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; biomarkers; cerebrospinal fluid; dementia; neurovascular unit

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ANIMAL; ASTROCYTE; BRAIN; CEREBROSPINAL FLUID; DEMENTIA; DIET; ENDOTHELIUM CELL; EXERCISE; HUMAN; METABOLISM; MICROGLIA; PATHOLOGY; PATHOPHYSIOLOGY; PERICYTE; PHYSIOLOGICAL STRESS; VASCULARIZATION;

ALZHEIMER DISEASE; ANIMALS; ASTROCYTES; BIOLOGICAL MARKERS; BRAIN; DEMENTIA; DIET; ENDOTHELIAL CELLS; EXERCISE; HUMANS; MICROGLIA; PERICYTES; STRESS, PHYSIOLOGICAL;

EID: 84934444613     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.76     Document Type: Review

References (222)

1. Prince M, Albanese E, Guerchet M, Prina M. World Alzheimer Report 2014: dementia and risk reduction: an analysis of protective and modifiable factors. Alzheimers Dis Int 2014, 1-99
2. Alzheimer's Association. 2014 Alzheimer's disease facts and figures. Alzheimers Dement 2014; 10: e47-e92
3. Sano M, Dahlman K, Sewell M, Zhu CW. The economics of caring for individuals with Alzheimer's disease: caregiving for Alzheimer's Disease and related disorders. Springer: New York, 2013
4. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202-208
5. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57: 178-201
6. Lo EH, Rosenberg GA. The neurovascular unit in health and disease: introduction. Stroke 2009; 40: S2-S3
7. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011; 42: 2672-2713
8. Vickrey BG, Brott TG, Koroshetz WJ. Stroke Research Priorities Meeting Steering Committee and the National Advisory Neurological Disorders and Stroke Council, National Institute of Neurological Disorders and Stroke. Research priority setting: a summary of the 2012 NINDS Stroke Planning Meeting Report. Stroke 2013; 44: 2338-2342
9. Montine T. Conference and recommendations report to the NINDS Council. Bethesda, Maryland, 2013 http://www.ninds.nih.gov/funding/areas/neurodegen eration/workshops/adrd2013/ADRD-2013-Report-And-Memorandum-508comp. pdf (accessed 22 Jan 2014
10. Montine TJ, Koroshetz WJ, Babcock D, Dickson DW, Galpern WR, Glymour MM, et al. Recommendations of the Alzheimer's disease-related dementias conference. Neurology 2014; 83: 851-860
11. National Plan to Address Alzheimer's Disease: 2013 Update. 2013. http://aspe. hhs.gov/daltcp/napa/natlplan.shtml (accessed 27 Nov 2013
12. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-738
13. Iadecola C. The pathobiology of vascular dementia. Neuron 2013; 80: 844-866
14. Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, et al. Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 2014; 10: 109-114
15. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-360
16. Van Broeck B, Van Broeckhoven C, Kumar-Singh S. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Neurodegener Dis 2007; 4: 349-365
17. Zlokovic BV. Neurodegeneration and the neurovascular unit. Nat Med 2010; 16: 1370-1371
18. Grammas P, Sanchez A, Tripathy D, Luo E, Martinez J. Vascular signaling abnormalities in Alzheimer disease. Cleve Clin J Med 2011; 78 Suppl 1: S50-S53
19. Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci 2012; 322: 141-147
20. Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. JAMA Neurol 2013; 70: 440-444
21. Winkler EA, Sagare AP, Zlokovic BV. The pericyte: a forgotten cell type with important implications for Alzheimer's disease? Brain Pathol 2014; 24: 371-386
22. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004; 62: 1148-1155
23. Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011; 42: 722-727
24. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol 2012; 11: 272-282
25. Toledo JB, Arnold SE, Raible K, Brettschneider J, Xie SX, Grossman M, et al. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain 2013; 136: 2697-2706
26. Zlokovic BV, Begley DJ, Chain-Eliash DG. Blood-brain barrier permeability to leucine-enkephalin, D-Alanine2-D-leucine5-enkephalin and their N-Terminal amino acid (tyrosine). Brain Res 1985; 336: 125-132
27. Zloković BV, Segal MB, Begley DJ, Davson H, Rakić L. Permeability of the bloodcerebrospinal fluid and blood-brain barriers to thyrotropin-releasing hormone. Brain Res 1985; 358: 191-199
28. Zlokovic BV. Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier. Pharm Res 1995; 12: 1395-1406
29. Zloković BV, Lipovac MN, Begley DJ, Davson H, Rakić L. Transport of leucineenkephalin across the blood-brain barrier in the perfused guinea pig brain. J Neurochem 1987; 49: 310-315
30. Mann GE, Zlokovic BV, Yudilevich DL. Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon. Biochim Biophys Acta 1985; 819: 241-248
31. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for bloodbrain barrier integrity during embryogenesis. Nature 2010; 468: 562-566
32. Armulik A, Genové G, Mäe M, Nisancioglu MH, Wallgard E, Niaudet C, et al. Pericytes regulate the blood-brain barrier. Nature 2010; 468: 557-561
33. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010; 68: 409-427
34. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012; 485: 512-516
35. Winkler EA, Sengillo JD, Bell RD, Wang J, Zlokovic BV. Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J Cereb Blood Flow Metab 2012; 32: 1841-1852
36. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, et al. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest 2002; 32: 360-371
37. Salloway S, Gur T, Berzin T, Tavares R, Zipser B, Correia S, et al. Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease. J Neurol Sci 2002; 203-204: 183-187
38. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007; 28: 977-986
39. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med 2009; 13: 2911-2925
40. Hultman K, Strickland S, Norris EH. The APOE e4/e4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients. J Cereb Blood Flow Metab 2013; 33: 1251-1258
41. Sengillo JD, Winkler EA, Walker CT, Sullivan JS, Johnson M, Zlokovic BV. Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol 2013; 23: 303-310
42. Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol 2001; 64: 575-611
43. Baloyannis SJ, Baloyannis IS. The vascular factor in Alzheimer's disease: a study in Golgi technique and electron microscopy. J Neurol Sci 2012; 322: 117-121
44. Cullen KM, Kócsi Z, Stone J. Pericapillary haem-rich deposits: evidence for microhaemorrhages in aging human cerebral cortex. J Cereb Blood Flow Metab 2005; 25: 1656-1667
45. Goos JDC, Kester MI, Barkhof F, Klein M, Blankenstein MA, Scheltens P, et al. Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke 2009; 40: 3455-3460
46. Zonneveld HI, Goos JDC, Wattjes MP, Prins ND, Scheltens P, van der Flier WM, et al. Prevalence of cortical superficial siderosis in a memory clinic population. Neurology 2014; 82: 698-704
47. Raven EP, Lu PH, Tishler TA, Heydari P, Bartzokis G. Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging. J Alzheimers Dis 2013; 37: 127-136
48. Starr JM, Farrall AJ, Armitage P, McGurn B, Wardlaw J. Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study. Psychiatry Res 2009; 171: 232-241
49. Wang H, Golob EJ, Su M-Y. Vascular volume and blood-brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls. J Magn Reson Imaging 2006; 24: 695-700
50. Larsson HBW, Courivaud F, Rostrup E, Hansen AE. Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 tesla. Magn Reson Med 2009; 62: 1270-1281
51. Cramer SP, Simonsen H, Frederiksen JL, Rostrup E, Larsson HBW. Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. Neuroimage Clin 2014; 4: 182-189
52. Taheri S, Gasparovic C, Shah NJ, Rosenberg GA. Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping. Magn Reson Med 2011; 65: 1036-1042
53. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015; 85: 296-302
54. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9: 907-913
55. Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 2007; 204: 1999-2008
56. Li J-C, Han L, Wen Y-X, Yang Y-X, Li S, Li X-S, et al. Increased permeability of the blood-brain barrier and Alzheimer's disease-like alterations in slit-2 transgenic mice. J Alzheimers Dis 2014; 43: 535-548
57. Smith CD, Andersen AH, Kryscio RJ, Schmitt FA, Kindy MS, Blonder LX, et al. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 1999; 53: 1391-1396
58. Ruitenberg A, den Heijer T, Bakker SLM, van Swieten JC, Koudstaal PJ, Hofman A, et al. Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 2005; 57: 789-794
59. Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, et al. Cerebral blood flow in Alzheimer's disease. Vasc Health Risk Manag 2012; 8: 599-611
60. Thambisetty M, Beason-Held L, An Y, Kraut MA, Resnick SM. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch Neurol 2010; 67: 93-98
61. Wierenga CE, Hays CC, Zlatar ZZ. Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease. J Alzheimers Dis 2014; 42 Suppl 4: S411-S419
62. Johnson NA, Jahng G-H, Weiner MW, Miller BL, Chui HC, Jagust WJ, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005; 234: 851-859
63. Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 2004; 366: 80-85
64. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, et al. Inhibition of angiogenesis by Abeta peptides. Angiogenesis 2004; 7: 75-85
65. Zhang X, Li G, Guo L, Nie K, Jia Y, Zhao L, et al. Age-related alteration in cerebral blood flow and energy failure is correlated with cognitive impairment in the senescence-Accelerated prone mouse strain 8 (SAMP8). Neurol Sci 2013; 34: 1917-1924
66. Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 2013; 4: 2932
67. Kumar-Singh S, Pirici D, McGowan E, Serneels S, Ceuterick C, Hardy J, et al. Densecore plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol 2005; 167: 527-543
68. Deng D, Xu C, Sun P, Wu J, Yan C, Hu M, et al. Crystal structure of the human glucose transporter GLUT1. Nature 2014; 510: 121-125
69. Allen A, Messier C. Plastic changes in the astrocyte GLUT1 glucose transporter and beta-Tubulin microtubule protein following voluntary exercise in mice. Behav Brain Res 2013; 240: 95-102
70. Choeiri C, Staines W, Miki T, Seino S, Messier C. Glucose transporter plasticity during memory processing. Neuroscience 2005; 130: 591-600
71. Zeller K, Rahner-Welsch S, Kuschinsky W. Distribution of Glut1 glucose transporters in different brain structures compared to glucose utilization and capillary density of adult rat brains. J Cereb Blood Flow Metab 1997; 17: 204-209
72. Ossenkoppele R, van der Flier WM, Zwan MD, Adriaanse SF, Boellaard R, Windhorst AD, et al. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 2013; 80: 359-365
73. Protas HD, Chen K, Langbaum JBS, Fleisher AS, Alexander GE, Lee W, et al. Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-Aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol 2013; 70: 320-325
74. Mosconi L, Rinne JO, Tsui WH, Murray J, Li Y, Glodzik L, et al. Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging 2013; 34: 22-34
75. Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 2006; 47: 1778-1786
76. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol Dis 2002; 9: 61-68
77. Jagust WJ, Seab JP, Huesman RH, Valk PE, Mathis CA, Reed BR, et al. Diminished glucose transport in Alzheimer's disease: dynamic PET studies. J Cereb Blood Flow Metab 1991; 11: 323-330
78. Piert M, Koeppe RA, Giordani B, Berent S, Kuhl DE. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J Nucl Med 1996; 37: 201-208
79. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 1994; 35: 546-551
80. Mooradian AD, Chung HC, Shah GN. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. Neurobiol Aging 1997; 18: 469-474
81. Kalaria RN, Harik SI. Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. J Neurochem 1989; 53: 1083-1088
82. Horwood N, Davies DC. Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease. Virchows Arch 1994; 425: 69-72
83. Zheng P-P, Romme E, van der Spek PJ, Dirven CMF, Willemsen R, Kros JM. Glut1/SLC2A1 is crucial for the development of the blood-brain barrier in vivo. Ann Neurol 2010; 68: 835-844
84. Levy E, Prelli F, Frangione B. Studies on the first described Alzheimer's disease amyloid beta mutant, the Dutch variant. J Alzheimers Dis 2006; 9: 329-339
85. Haacke EM, DelProposto ZS, Chaturvedi S, Sehgal V, Tenzer M, Neelavalli J, et al. Imaging cerebral amyloid angiopathy with susceptibility-weighted imaging. AJNR Am J Neuroradiol 2007; 28: 316-317
86. Heringa SM, Reijmer YD, Leemans A, Koek HL, Kappelle LJ, Biessels GJ, et al. Multiple microbleeds are related to cerebral network disruptions in patients with early Alzheimer's disease. J Alzheimers Dis 2014; 38: 211-221
87. Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 2002; 109: 813-836
88. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid betapeptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004; 43: 333-344
89. Monro OR, Mackic JB, Yamada S, Segal MB, Ghiso J, Maurer C, et al. Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 2002; 23: 405-412
90. Hawkes CA, Sullivan PM, Hands S, Weller RO, Nicoll JAR, Carare RO. Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE e4 allele. PLoS One 2012; 7: e41636
91. Weller RO, Boche D, Nicoll JAR. Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol (Berl) 2009; 118: 87-102
92. Li H, Guo Q, Inoue T, Polito VA, Tabuchi K, Hammer RE, et al. Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. Mol Neurodegener 2014; 9: 28
93. Karch CM, Cruchaga C, Goate AM. Alzheimer's disease genetics: from the bench to the clinic. Neuron 2014; 83: 11-26
94. Small SA, Gandy S. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. Neuron 2006; 52: 15-31
95. Szpak GM, Lewandowska E, Wierzba-Bobrowicz T, Bertrand E, Pasennik E, Mendel T, et al. Small cerebral vessel disease in familial amyloid and non-Amyloid angiopathies: FAD-PS-1 (P117L) mutation and CADASIL. Immunohistochemical and ultrastructural studies. Folia Neuropathol 2007; 45: 192-204
96. Armstrong RA. Spatial correlations between beta-Amyloid (Abeta) deposits and blood vessels in familial Alzheimer's disease. Folia Neuropathol 2008; 46: 241-248
97. Basum H, Bogdanovic N, Ingelsson M, Almkvist O, Naslund J, Axelman K, et al. Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease. Arch Neurol 2008; 65: 499-505
98. Niwa A, Matsuo K, Shindo A, Yata K, Shiraishi T, Tomimoto H. Clinical and neuropathological findings in a patient with familial Alzheimer disease showing a mutation in the PSEN1 gene: familial Alzheimer disease with PSEN1. Neuropathology 2013; 33: 199-203
99. Kelly P, McClean P, Ackermann M, Konerding MA, Hölscher C, Mitchell CA. Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide(TM). Microcirculation 2014; 22: 133-145
100. Gama Sosa MA, Gasperi RD, Rocher AB, Wang AC-J, Janssen WGM, Flores T, et al. Age-related vascular pathology in transgenic mice expressing presenilin 1-Associated familial Alzheimer's disease mutations. Am J Pathol 2010; 176: 353-368
101. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16: 903-907
102. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008; 118: 4002-4013
103. Halliday MR, Pomara N, Sagare AP, Mack WJ, Frangione B, Zlokovic BV. Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol 2013; 70: 1198-1200
104. Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, et al. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab 2015. doi: 10.1038/jcbfm.2015.44
105. Ringman JM, Sachs MC, Zhou Y, Monsell SE, Saver JL, Vinters HV. Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease. JAMA Neurol 2014; 71: 878-883
106. Suri S, Mackay CE, Kelly ME, Germuska M, Tunbridge EM, Frisoni GB, et al. Reduced cerebrovascular reactivity in young adults carrying the APOE e4 allele. Alzheimers Dement 2014. doi: 10.1016/j.jalz.2014.05.1755
107. Alata W, Ye Y, St-Amour I, Vandal M, Calon F. Human apolipoprotein E e4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J Cereb Blood Flow Metab 2015; 35: 86-94
108. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093
109. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-435
110. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-Analysis of 74, 046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-1458
111. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007; 27: 909-918
112. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, et al. ADAM10 missense mutations potentiate β-Amyloid accumulation by impairing prodomain chaperone function. Neuron 2013; 80: 385-401
113. Tanzi RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: pii: a006296
114. Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med 2013; 369: 2275-2277
115. Glodzik L, Mosconi L, Tsui W, de Santi S, Zinkowski R, Pirraglia E, et al. Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiol Aging 2012; 33: 1215-1227
116. Stonehouse W, Conlon CA, Podd J, Hill SR, Minihane AM, Haskell C, et al. DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial. Am J Clin Nutr 2013; 97: 1134-1143
117. Fonteh AN, Cipolla M, Chiang J, Arakaki X, Harrington MG. Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer's disease. PLoS One 2014; 9: e100519
118. Nguyen LN, Ma D, Shui G, Wong P, Cazenave-Gassiot A, Zhang X, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 2014; 509: 503-506
119. Ben-Zvi A, Lacoste B, Kur E, Andreone BJ, Mayshar Y, Yan H, et al. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature 2014; 509: 507-511
120. Zhao Z, Zlokovic BV. Blood-brain barrier: a dual life of MFSD2A? Neuron 2014; 82: 728-730
121. Vandal M, Alata W, Tremblay C, Rioux-Perreault C, Salem N, Calon F, et al. Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2. J Neurochem 2014; 129: 516-526
122. Brickman AM, Khan UA, Provenzano FA, Yeung L-K, Suzuki W, Schroeter H, et al. Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. Nat Neurosci 2014; 17: 1798-1803
123. Montagne A, Pa J, Zlokovic BV. Vascular plasticity and cognition during normal aging and dementia. JAMA Neurol 2015. doi: 10.1001/jamaneurol. 2014.4636
124. Defina LF, Willis BL, Radford NB, Gao A, Leonard D, Haskell WL, et al. The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study. Ann Intern Med 2013; 158: 162-168
125. Lazarov O, Robinson J, Tang Y-P, Hairston IS, Korade-Mirnics Z, Lee VM-Y, et al. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005; 120: 701-713
126. Ambrée O, Leimer U, Herring A, Görtz N, Sachser N, Heneka MT, et al. Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways. Am J Pathol 2006; 169: 544-552
127. Herring A, Yasin H, Ambrée O, Sachser N, Paulus W, Keyvani K. Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol 2008; 18: 32-39
128. Kanekiyo T, Liu C-C, Shinohara M, Li J, Bu G. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. J Neurosci 2012; 32: 16458-16465
129. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, LaRue B, et al. A multimodal RAGEspecific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 2012; 122: 1377-1392
130. Craig-Schapiro R, Fagan AM, Holtzman DM. Biomarkers of Alzheimer's disease. Neurobiol Dis 2009; 35: 128-140
131. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009; 461: 916-922
132. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144
133. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 2011; 3: 89ra57
134. Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013; 80: 1784-1791
135. Gandy S. Alzheimer's disease: new data highlight nonneuronal cell types and the necessity for presymptomatic prevention strategies. Biol Psychiatry 2014; 75: 553-557
136. Iadecola C, Davisson RL. Hypertension and cerebrovascular dysfunction. Cell Metab 2008; 7: 476-484
137. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Bloodbrain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol Scand 1990; 81: 323-326
138. Blennow K, Wallin A, Uhlemann C, Gottfries CG. White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand 1991; 83: 187-193
139. Wallin A, Blennow K, Rosengren L. Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype. Alzheimer Dis Assoc Disord 1999; 13 Suppl 3: S102-S105
140. Skoog I, Wallin A, Fredman P, Hesse C, Aevarsson O, Karlsson I, et al. A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology 1998; 50: 966-971
141. Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 2011; 6: e18850
142. Muradashvili N, Qipshidze N, Munjal C, Givvimani S, Benton RL, Roberts AM, et al. Fibrinogen-induced increased pial venular permeability in mice. J Cereb Blood Flow Metab 2012; 32: 150-163
143. Martorana A, Sancesario GM, Esposito Z, Nuccetelli M, Sorge R, Formosa A, et al. Plasmin system of Alzheimer's disease patients: CSF analysis. J Neural Transm 2012; 119: 763-769
144. Hanzel CE, Iulita MF, Eyjolfsdottir H, Hjorth E, Schultzberg M, Eriksdotter M, et al. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. J Alzheimers Dis 2014; 40: 667-678
145. Winkler EA, Bell RD, Zlokovic BV. Central nervous system pericytes in health and disease. Nat Neurosci 2011; 14: 1398-1405
146. Park L, Zhou J, Zhou P, Pistick R, El Jamal S, Younkin L, et al. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc Natl Acad Sci USA 2013; 110: 3089-3094
147. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 2014; 508: 55-60
148. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (Berl) 2010; 119: 669-678
149. Uzawa A, Mori M, Masuda S, Kuwabara S. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch Neurol 2011; 68: 913-917
150. Toneatto S, Finco O, van der Putten H, Abrignani S, Annunziata P. Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS 1999; 13: 2343-2348
151. Nielsen HM, Londos E, Minthon L, Janciauskiene SM. Soluble adhesion molecules and angiotensin-converting enzyme in dementia. Neurobiol Dis 2007; 26: 27-35
152. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660
153. Jefferies WA, Price KA, Biron KE, Fenninger F, Pfeifer CG, Dickstein DL. Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease. Alzheimers Res Ther 2013; 5: 64
154. Bogaert E, Van Damme P, Van Den Bosch L, Robberecht W. Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. Muscle Nerve 2006; 34: 391-405
155. Tarkowski E, Issa R, Sjögren M, Wallin A, Blennow K, Tarkowski A, et al. Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 2002; 23: 237-243
156. Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, et al. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 2005; 11: 959-965
157. Xing C, Hayakawa K, Lok J, Arai K, Lo EH. Injury and repair in the neurovascular unit. Neurol Res 2012; 34: 325-330
158. Alvarez JI, Katayama T, Prat A. Glial influence on the blood brain barrier. Glia 2013; 61: 1939-1958
159. Mrak RE, Griffinbc WS. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol Aging 2001; 22: 915-922
160. Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 2010; 58: 300-314
161. Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochem Int 2001; 39: 409-413
162. Nooijen PT, Schoonderwaldt HC, Wevers RA, Hommes OR, Lamers KJ. Neuronspecific enolase, S-100 protein, myelin basic protein and lactate in CSF in dementia. Dement Geriatr Cogn Disord 1997; 8: 169-173
163. Li Y, Barger SW, Liu L, Mrak RE, Griffin WS. S100beta induction of the proinflammatory cytokine interleukin-6 in neurons. J Neurochem 2000; 74: 143-150
164. Guillot-Sestier M-V, Town T. Innate immunity in Alzheimer's disease: a complex affair. CNS Neurol Disord Drug Targets 2013; 12: 593-607
165. Brosseron F, Krauthausen M, Kummer M, Heneka MT. Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol 2014; 50: 534-544
166. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 1200-1205
167. Richartz E, Stransky E, Batra A, Simon P, Lewczuk P, Buchkremer G, et al. Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease? J Psychiatr Res 2005; 39: 535-543
168. Jia JP, Meng R, Sun YX, Sun WJ, Ji XM, Jia LF. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci Lett 2005; 383: 12-16
169. Engelborghs S, De Brabander M, De Crée J, D'Hooge R, Geerts H, Verhaegen H, et al. Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-Alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem Int 1999; 34: 523-530
170. Yamada K, Kono K, Umegaki H, Yamada K, Iguchi A, Fukatsu T, et al. Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-Type dementia. Neurosci Lett 1995; 186: 219-221
171. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202: 17-20
172. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 2006; 63: 538-543
173. Hampel H, Teipel SJ, Padberg F, Haslinger A, Riemenschneider M, Schwarz MJ, et al. Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease. Brain Res 1999; 823: 104-112
174. Amlien IK, Fjell AM. Diffusion tensor imaging of white matter degeneration in Alzheimer's disease and mild cognitive impairment. Neuroscience 2014; 276C: 206-215
175. Nir TM, Jahanshad N, Villalon-Reina JE, Toga AW, Jack CR, Weiner MW, et al. Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. Neuroimage Clin 2013; 3: 180-195
176. Haight TJ, Landau SM, Carmichael O, Schwarz C, DeCarli C, Jagust WJ, et al. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol 2013; 70: 1039-1045
177. Yoshita M, Fletcher E, Harvey D, Ortega M, Martinez O, Mungas DM, et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006; 67: 2192-2198
178. Zhan X, Jickling GC, Ander BP, Liu D, Stamova B, Cox C, et al. Myelin injury and degraded myelin vesicles in Alzheimer's disease. Curr Alzheimer Res 2014; 11: 232-238
179. Yanagisawa K, Quarles RH, Johnson D, Brady RO, Whitaker JN. A derivative of myelin-Associated glycoprotein in cerebrospinal fluid of normal subjects and patients with neurological disease. Ann Neurol 1985; 18: 464-469
180. Greenberg SM, Grabowski T, Gurol ME, Skehan ME, Nandigam RNK, Becker JA, et al. Detection of isolated cerebrovascular beta-Amyloid with Pittsburgh compound B. Ann Neurol 2008; 64: 587-591
181. Villemagne VL, Pike KE, Ch?telat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 2011; 69: 181-192
182. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-Amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry 2004; 9: 705-710
183. de Souza LC, Sarazin M, Teixeira-Júnior AL, Caramelli P, Santos AE, dos, Dubois B. Biological markers of Alzheimer's disease. Arq Neuropsiquiatr 2014; 72: 227-231
184. Steenland K, Zhao L, Goldstein F, Cellar J, Lah J. Biomarkers for predicting cognitive decline in those with normal cognition. J Alzheimers Dis 2014; 40: 587-594
185. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-Amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014; 71: 1282-1289
186. Buerger K, Teipel SJ, Zinkowski R, Sunderland T, Andreasen N, Blennow K, et al. Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment. Neurosci Lett 2005; 391: 48-50
187. Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002; 59: 627-629
188. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, et al. Cerebrospinal fluid beta-Amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 2004; 56: 670-676
189. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging 2010; 31: 1284-1303
190. Hu Y-Y, He S-S, Wang X-C, Duan Q-H, Khatoon S, Iqbal K, et al. Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002; 320: 156-160
191. Sjögren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000; 54: 1960-1964
192. Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? Funct Neurol 2008; 23: 93-96
193. Schmidt FM, Mergl R, Stach B, Jahn I, Gertz H-J, Schönknecht P. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease. Neurosci Lett 2014; 570: 81-85
194. Zhu X, Raina AK, Lee H-G, Casadesus G, Smith MA, Perry G. Oxidative stress signalling in Alzheimer's disease. Brain Res 2004; 1000: 32-39
195. Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease. J Alzheimers Dis 2011; 24: 25-34
196. Liguori C, Stefani A, Sancesario G, Sancesario GM, Marciani MG, Pierantozzi M. CSF lactate levels, t proteins, cognitive decline: a dynamic relationship in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2014. doi: 10.1136/jnnp-2014-308577
197. Saeed AA, Genové G, Li T, Lütjohann D, Olin M, Mast N, et al. Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain. J Biol Chem 2014; 289: 23712-23722
198. Popp J, Lewczuk P, Kölsch H, Meichsner S, Maier W, Kornhuber J, et al. Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. J Neurochem 2012; 123: 310-316
199. Keeney JTR, Swomley AM, Förster S, Harris JL, Sultana R, Butterfield DA. Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration. Proteomics Clin Appl 2013; 7: 109-122
200. Gustaw-Rothenberg K, Lerner A, Bonda DJ, Lee H, Zhu X, Perry G, et al. Biomarkers in Alzheimer's disease: past, present and future. Biomark Med 2010; 4: 15-26
201. Nation DA, Edland SD, Bondi MW, Salmon DP, Delano-Wood L, Peskind ER, et al. Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology 2013; 81: 2024-2027
202. Glodzik L, Rusinek H, Pirraglia E, McHugh P, Tsui W, Williams S, et al. Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly. Neurobiol Aging 2014; 35: 64-71
203. Corrêa JD, Starling D, Teixeira AL, Caramelli P, Silva TA. Chemokines in CSF of Alzheimer's disease patients. Arq Neuropsiquiatr 2011; 69: 455-459
204. Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 2014; 10: 115-131
205. Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, et al. Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis 2014; 38: 515-531
206. Rembach A, Ryan TM, Roberts BR, Doecke JD, Wilson WJ, Watt AD, et al. Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. Biomark Med 2013; 7: 641-662
207. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2012; 8: 65-73
208. Gnanapavan S, Hegen H, Khalil M, Hemmer B, Franciotta D, Hughes S, et al. Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology 2014; 83: 1210-1216
209. Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2014; 10: 808-817
210. Winkler EA, Sengillo JD, Sagare AP, Zhao Z, Ma Q, Zuniga E, et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALSmodel mice. Proc Natl Acad Sci USA 2014; 111: E1035-E1042
211. Dömötör E, Benzakour O, Griffin JH, Yule D, Fukudome K, Zlokovic BV. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 2003; 101: 4797-4801
212. Griffin JH, Zlokovic B, Fernández JA. Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke. Semin Hematol 2002; 39: 197-205
213. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, et al. Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms. Nat Med 2009; 15: 649-656
214. Ahn HJ, Zamolodchikov D, Cortes-Canteli M, Norris EH, Glickman JF, Strickland S. Alzheimer's disease peptide beta-Amyloid interacts with fibrinogen and induces its oligomerization. Proc Natl Acad Sci USA 2010; 107: 21812-21817
215. Ahn HJ, Glickman JF, Poon KL, Zamolodchikov D, Jno-Charles OC, Norris EH, et al. A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. J Exp Med 2014; 211: 1049-1062
216. Hammer C, Stepniak B, Schneider A, Papiol S, Tantra M, Begemann M, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry 2013; 19: 1143-1149
217. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009; 8: 16-30
218. Liu R, Wu C-X, Zhou D, Yang F, Tian S, Zhang L, et al. Pinocembrin protects against β-Amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis. BMC Med 2012; 10: 105
219. Meng F, Liu R, Gao M, Wang Y, Yu X, Xuan Z, et al. Pinocembrin attenuates bloodbrain barrier injury induced by global cerebral ischemia-reperfusion in rats. Brain Res 2011; 1391: 93-101
220. Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, et al. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology 2014; 82: 1536-1542
221. Fleming JO, Carlsson CM. Biomarkers for neurology: guides and lines. Neurology 2014; 83: 1130-1131
222. Selkoe DJ. Preventing Alzheimer's disease. Science 2012; 337: 1488-1492